The present invention refers to exosomes obtained from fibro-adipogenic progenitors (FAPs) previously exposed to histone deacetylase (HDAC) inhibitors. It also relatesto such exosomes for the use in the treatment of muscular dystrophies, in particular in the treatment of Duchenne Muscular Dystrophy. Pharmaceutical compositions comprising such exosomes and their medical uses are also within the scope of the present invention.